Form 8-K PROTEOSTASIS THERAPEUTIC For: Mar 12

Go back to Form 8-K PROTEOSTASIS THERAPEUTIC For: Mar 12

Proteostasis Therapeutics (PTI) Surges 50% on FDA Breakthrough Therapy Designation for PTI-428

March 13, 2018 9:05 AM EDT

Proteostasis Therapeutics (NASDAQ: PTI) surges 50% in pre-open trading after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for PTI-428, the Companys cystic fibrosis transmembrane conductance regulator (CFTR) amplifier.

... More